RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer

by Erik J. vanHelden, Lindsay Angus, C. Willemien Menke‐van der Houven van Oordt, Daniëlle A. M. Heideman, Eline Boon, Suzanne C. vanEs, Sandra A. Radema, Carla M. L. vanHerpen, Derk Jan A. deGroot, Elisabeth G. E. deVries, Maurice P. H. M. Jansen, Stefan Sleijfer, Henk M. W. Verheul
Published 2019-11-01